Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma

NCT02649829 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT02649829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02649829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma
Lead sponsor
University Hospital, Antwerp
Phase
Phase 1/2
Overall status
Completed
Start date
October 3, 2017
Completion date
March 9, 2025
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma